skip to Main Content

IBT Receives Phase I SBIR grant from NIAID for development of neutralizing monoclonal antibodies against Marburg Virus

IBT in collaboration with the laboratory of Dr. Yuxing Li, at the University of Maryland, and Dr. Tom Geisbert laboratory and University of Texas Medical Branch (UTMB) receive a collaborative SBIR grant from NIH, entitled Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein.

Marburg virus has caused highly lethal outbreaks in the last few decades.  Currently there is only a single class of antibodies known to neutralize marburgviruses.   Under this grant IBT investigator Dr. M. Javad Aman with work with Dr. Li’s team to develop novel monoclonal antibodies from B cells of macaques immunized with IBT’s proprietary vaccine candidates. These antibodies will be tested in rodents and nonhuman primates at UTMB to select lead therapeutic candidates.

Back To Top
×Close search
Search